Literature DB >> 29947124

Ascertainment and validation of major bleeding events in a primary care database.

Ana Ruigómez1, Gunnar Brobert2, Kiliana Suzart-Woischnik3, Luis Alberto García-Rodríguez1.   

Abstract

PURPOSE: The purpose of the study is to evaluate the impact of validation on the identification of major bleeding events in The Health Improvement Network (THIN) database in patients receiving anticoagulant therapy.
METHODS: Patients aged 2 to 89 years with a first prescription for an anticoagulant (rivaroxaban or warfarin) between 2012 and 2015 were identified in THIN. Major bleeding events, defined as bleeding events necessitating hospitalization or referral to accident and emergency services or a specialist clinic, were identified using a 2-step ascertainment process based on read codes only, and then validated using a 2-step process requiring manual review of patients' records.
RESULTS: The positive predictive value for the ascertainment of major intracranial (IC) bleeds using only read codes was 96.9%, compared with 70.4% for gastrointestinal (GI) bleeds and 64.1% for urogenital (UG) bleeds. The incidence rate of major IC bleeding events was therefore similar when it was calculated before and after validation (0.32 per 100 person-years and 0.31 per 100 person-years, respectively). The incidence rate of major GI bleeds identified using read codes alone was reduced following validation from 2.05 to 0.94 per 100 person-years, and that of major UG bleeds decreased from 2.45 to 1.11 per 100 person-years.
CONCLUSIONS: Major GI and UG bleeding events ascertained from THIN using read codes require validation using additional information to prevent outcome misclassification. The absence of validation may lead to overestimated incidence rates of major bleeding for GI and UG bleeds.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  anticoagulants; bleeding; databases; pharmacoepidemiology; primary care; rivaroxaban; validation studies

Mesh:

Substances:

Year:  2018        PMID: 29947124     DOI: 10.1002/pds.4580

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

1.  Increasing use of anticoagulants in Germany and its impact on hospitalization rates for genitourinary bleeding.

Authors:  Olga von Beckerath; Alexander Matthias Paulitschek; Knut Kröger; Bernd Kowall; Frans Santosa; Andreas Stang
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

2.  Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study.

Authors:  Jacques Bouget; Frédéric Balusson; Maxime Maignan; Laure Pavageau; Pierre-Marie Roy; Karine Lacut; Lucie-Marie Scailteux; Emmanuel Nowak; Emmanuel Oger
Journal:  Br J Clin Pharmacol       Date:  2020-06-01       Impact factor: 4.335

3.  Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department.

Authors:  Emmanuel Oger; Marie-Anne Botrel; Catherine Juchault; Jacques Bouget
Journal:  BMC Med Res Methodol       Date:  2019-10-18       Impact factor: 4.615

4.  Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network.

Authors:  Ana Ruigómez; Gunnar Brobert; Pareen Vora; Luis A García Rodríguez
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-10-12       Impact factor: 2.890

5.  Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.

Authors:  Patrick C Souverein; Hendrika A van den Ham; Consuelo Huerta; Elisa Martín Merino; Dolores Montero; Luz M León-Muñoz; Sven Schmiedl; Andreas Heeke; Marietta Rottenkolber; Morten Andersen; Mia Aakjaer; Marie L De Bruin; Olaf H Klungel; Helga Gardarsdottir
Journal:  Br J Clin Pharmacol       Date:  2020-07-13       Impact factor: 3.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.